Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays (Q42532626)

1 November 2017

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays (English)

1 reference

1 November 2017

5

Deenan Pillay

1 reference

1 November 2017

Ravindra K Gupta

1

1 reference

1 November 2017

Arinder Kohli

2

1 reference

1 November 2017

Adele L McCormick

3

1 reference

1 November 2017

Greg J Towers

4

1 reference

1 November 2017

Chris M Parry

6

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

1 November 2017

1 reference

1 November 2017

24

1 reference

1 November 2017

11

1 reference

1 November 2017

1651-1655

1 reference

Class-sparing regimens for initial treatment of HIV-1 infection

1 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2923069

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20597164

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20597164

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAD.0B013E3283398216

1 reference

release_xdwyex55vbctzoczrfvd22rvry

1 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xdwyex55vbctzoczrfvd22rvry

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

1 November 2017

1 reference